Court Ruled Against Vanda in Generic Drug Patent Case
The Delaware court ruling allows Teva and Apotex to continue selling generic alternatives to HETLIOZ.
Updated on Oct. 1, 2026 in Healthcare
Live Poll
Should pharmaceutical companies be held responsible for off-label uses of their medications by patients?
The District of Delaware ruled that generic drug labels for tasimelteon do not induce infringement of Vanda Pharmaceuticals Inc. patents. The decision impacts manufacturers by clarifying that labels mirroring reference drug warnings regarding beta-blocker interactions do not constitute affirmative steps toward infringement.
Why it matters
This ruling limits the ability of brand-name manufacturers to use label-based infringement claims to block generic competition when labels simply reflect safety warnings. It reinforces a standard requiring clear evidence that a generic manufacturer is actively promoting infringing use.
The District of Delaware cleared Teva and Apotex, whose generic applications were first filed in 2018, to compete against 20 mg HETLIOZ capsules. The ruling addresses patents that are not slated to expire until 2033.
The players
Vanda Pharmaceuticals Inc.
A biopharmaceutical company that develops and commercializes therapies for circadian rhythm and sleep-wake disorders.
Teva Pharmaceuticals USA, Inc.
A global generic drug manufacturer and supplier of specialty medicines.
Apotex
A pharmaceutical company specializing in the production and distribution of generic medications.
The details
The court applied the standard from the Hikma v. Amarin decision, determining that copying reference labels to warn of beta-adrenergic receptor antagonist interactions does not encourage infringing use. Vanda had argued that these labels promoted a specific, patented method of treatment, but the court found no evidence of intent to induce infringement. Substantial non-infringing use exists for the products, as many patients take the medication alongside beta-blockers without adhering to the patented discontinuation method.
Timeline
HETLIOZ 20 mg capsules were approved in 2014.
Teva and Apotex filed generic ANDAs in 2018.
The FDA approved the generic ANDAs in December 2022.
The Supreme Court decided Hikma v. Amarin on June 4, 2026.
Remaining counterclaims are set for trial in October 2026.
Market Landscape
This decision follows the legal standard established in the Supreme Court decision in Hikma v. Amarin regarding induced infringement. It marks a significant judicial application of that precedent in favor of generic market access.
Operators in the pharmaceutical space should monitor how courts apply the Hikma v. Amarin standard to label-based infringement claims in future patent disputes. Manufacturers should prepare for ongoing antitrust litigation following this summary judgment.
The takeaway
The court's dismissal of induced infringement claims suggests a high bar for brand-name companies seeking to block generics based on safety warnings. Legal counsel should track the upcoming October 2026 trial for further precedents regarding the scope of antitrust counterclaims in these disputes.
What happens next
Remaining counterclaims related to patent invalidity, inequitable conduct, and antitrust allegations are scheduled for trial in October 2026.
Further reading
For broader trends in pharmaceutical litigation, explore our Healthcare section.
Source note: This article includes information reported by The National Law Review - A Free To Use Nationwide Database of Legal Publications.
Live Poll
Should pharmaceutical companies be held responsible for off-label uses of their medications by patients?
